Randomized Trial of Adjuvant Thalidomide Versus Observation in Patients With Completely Resected High-Risk Renal Cell Carcinoma

Vitaly Margulis, Surena F. Matin, Nizar Tannir, Pheroze Tamboli, Yu Shen, Marisa Lozano, David A. Swanson, Eric Jonasch, Christopher G. Wood

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Objectives: To evaluate the effect of adjuvant thalidomide on recurrence-free survival (RFS) after nephrectomy for high-risk metastatic renal cell carcinoma (RCC). Methods: Eligibility criteria for enrollment on this randomized trial included any histologic subtype, T2 (high grade, any N), T3/T4 (any grade, any N), or node-positive (any grade, any T) RCC. We randomized eligible patients to observation or to receive thalidomide 300 mg daily for 24 months. Patients were observed until disease recurrence or death. Results: After we enrolled 46 patients, we stopped the trial at a median follow up of 43.9 months (range, 9.7-74.2 months). Patients on the thalidomide arm had inferior 2- and 3-year probabilities of RFS, compared with controls (47.8% vs 69.3% and 28.7% vs 69.3%, respectively; P = .022). The 2- and 3-year cancer-specific survival was similar for both groups. All observed deaths were attributable to RCC (P = .392). By multivariate analysis, tumor size and grade predicted recurrence (P = .001 and .013) and kidney cancer-specific death (P = .002 and .014). Thalidomide treatment, however, was not an independent predictor of recurrence or cancer-specific mortality. Conclusions: In this small, randomized, controlled trial, adjuvant thalidomide therapy after complete resection of high-risk RCC did not improve the 2- and 3-year RFS rates or cancer-specific death rates.

Original languageEnglish (US)
Pages (from-to)337-341
Number of pages5
JournalUrology
Volume73
Issue number2
DOIs
StatePublished - Feb 2009

Fingerprint

Thalidomide
Renal Cell Carcinoma
Observation
Recurrence
Survival
Neoplasms
Mortality
Kidney Neoplasms
Nephrectomy
Multivariate Analysis
Survival Rate
Randomized Controlled Trials
Therapeutics

ASJC Scopus subject areas

  • Urology

Cite this

Randomized Trial of Adjuvant Thalidomide Versus Observation in Patients With Completely Resected High-Risk Renal Cell Carcinoma. / Margulis, Vitaly; Matin, Surena F.; Tannir, Nizar; Tamboli, Pheroze; Shen, Yu; Lozano, Marisa; Swanson, David A.; Jonasch, Eric; Wood, Christopher G.

In: Urology, Vol. 73, No. 2, 02.2009, p. 337-341.

Research output: Contribution to journalArticle

Margulis, V, Matin, SF, Tannir, N, Tamboli, P, Shen, Y, Lozano, M, Swanson, DA, Jonasch, E & Wood, CG 2009, 'Randomized Trial of Adjuvant Thalidomide Versus Observation in Patients With Completely Resected High-Risk Renal Cell Carcinoma', Urology, vol. 73, no. 2, pp. 337-341. https://doi.org/10.1016/j.urology.2008.08.476
Margulis, Vitaly ; Matin, Surena F. ; Tannir, Nizar ; Tamboli, Pheroze ; Shen, Yu ; Lozano, Marisa ; Swanson, David A. ; Jonasch, Eric ; Wood, Christopher G. / Randomized Trial of Adjuvant Thalidomide Versus Observation in Patients With Completely Resected High-Risk Renal Cell Carcinoma. In: Urology. 2009 ; Vol. 73, No. 2. pp. 337-341.
@article{2af2a370591e42eaae73181ddf9b58de,
title = "Randomized Trial of Adjuvant Thalidomide Versus Observation in Patients With Completely Resected High-Risk Renal Cell Carcinoma",
abstract = "Objectives: To evaluate the effect of adjuvant thalidomide on recurrence-free survival (RFS) after nephrectomy for high-risk metastatic renal cell carcinoma (RCC). Methods: Eligibility criteria for enrollment on this randomized trial included any histologic subtype, T2 (high grade, any N), T3/T4 (any grade, any N), or node-positive (any grade, any T) RCC. We randomized eligible patients to observation or to receive thalidomide 300 mg daily for 24 months. Patients were observed until disease recurrence or death. Results: After we enrolled 46 patients, we stopped the trial at a median follow up of 43.9 months (range, 9.7-74.2 months). Patients on the thalidomide arm had inferior 2- and 3-year probabilities of RFS, compared with controls (47.8{\%} vs 69.3{\%} and 28.7{\%} vs 69.3{\%}, respectively; P = .022). The 2- and 3-year cancer-specific survival was similar for both groups. All observed deaths were attributable to RCC (P = .392). By multivariate analysis, tumor size and grade predicted recurrence (P = .001 and .013) and kidney cancer-specific death (P = .002 and .014). Thalidomide treatment, however, was not an independent predictor of recurrence or cancer-specific mortality. Conclusions: In this small, randomized, controlled trial, adjuvant thalidomide therapy after complete resection of high-risk RCC did not improve the 2- and 3-year RFS rates or cancer-specific death rates.",
author = "Vitaly Margulis and Matin, {Surena F.} and Nizar Tannir and Pheroze Tamboli and Yu Shen and Marisa Lozano and Swanson, {David A.} and Eric Jonasch and Wood, {Christopher G.}",
year = "2009",
month = "2",
doi = "10.1016/j.urology.2008.08.476",
language = "English (US)",
volume = "73",
pages = "337--341",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Randomized Trial of Adjuvant Thalidomide Versus Observation in Patients With Completely Resected High-Risk Renal Cell Carcinoma

AU - Margulis, Vitaly

AU - Matin, Surena F.

AU - Tannir, Nizar

AU - Tamboli, Pheroze

AU - Shen, Yu

AU - Lozano, Marisa

AU - Swanson, David A.

AU - Jonasch, Eric

AU - Wood, Christopher G.

PY - 2009/2

Y1 - 2009/2

N2 - Objectives: To evaluate the effect of adjuvant thalidomide on recurrence-free survival (RFS) after nephrectomy for high-risk metastatic renal cell carcinoma (RCC). Methods: Eligibility criteria for enrollment on this randomized trial included any histologic subtype, T2 (high grade, any N), T3/T4 (any grade, any N), or node-positive (any grade, any T) RCC. We randomized eligible patients to observation or to receive thalidomide 300 mg daily for 24 months. Patients were observed until disease recurrence or death. Results: After we enrolled 46 patients, we stopped the trial at a median follow up of 43.9 months (range, 9.7-74.2 months). Patients on the thalidomide arm had inferior 2- and 3-year probabilities of RFS, compared with controls (47.8% vs 69.3% and 28.7% vs 69.3%, respectively; P = .022). The 2- and 3-year cancer-specific survival was similar for both groups. All observed deaths were attributable to RCC (P = .392). By multivariate analysis, tumor size and grade predicted recurrence (P = .001 and .013) and kidney cancer-specific death (P = .002 and .014). Thalidomide treatment, however, was not an independent predictor of recurrence or cancer-specific mortality. Conclusions: In this small, randomized, controlled trial, adjuvant thalidomide therapy after complete resection of high-risk RCC did not improve the 2- and 3-year RFS rates or cancer-specific death rates.

AB - Objectives: To evaluate the effect of adjuvant thalidomide on recurrence-free survival (RFS) after nephrectomy for high-risk metastatic renal cell carcinoma (RCC). Methods: Eligibility criteria for enrollment on this randomized trial included any histologic subtype, T2 (high grade, any N), T3/T4 (any grade, any N), or node-positive (any grade, any T) RCC. We randomized eligible patients to observation or to receive thalidomide 300 mg daily for 24 months. Patients were observed until disease recurrence or death. Results: After we enrolled 46 patients, we stopped the trial at a median follow up of 43.9 months (range, 9.7-74.2 months). Patients on the thalidomide arm had inferior 2- and 3-year probabilities of RFS, compared with controls (47.8% vs 69.3% and 28.7% vs 69.3%, respectively; P = .022). The 2- and 3-year cancer-specific survival was similar for both groups. All observed deaths were attributable to RCC (P = .392). By multivariate analysis, tumor size and grade predicted recurrence (P = .001 and .013) and kidney cancer-specific death (P = .002 and .014). Thalidomide treatment, however, was not an independent predictor of recurrence or cancer-specific mortality. Conclusions: In this small, randomized, controlled trial, adjuvant thalidomide therapy after complete resection of high-risk RCC did not improve the 2- and 3-year RFS rates or cancer-specific death rates.

UR - http://www.scopus.com/inward/record.url?scp=58649102912&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58649102912&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2008.08.476

DO - 10.1016/j.urology.2008.08.476

M3 - Article

VL - 73

SP - 337

EP - 341

JO - Urology

JF - Urology

SN - 0090-4295

IS - 2

ER -